Portfolio

Velcera, Inc.

Developer of pet medication for the companion animal health industry, including the OTC flea and tick franchise, PetArmor®


Velcera was a leading companion animal health product company committed to providing consumers with best-in-class pet health products that contained the same active ingredients as branded veterinary products, but at a lower cost. With headquarters in Yardley, PennsylvaniaThe company’s products offered consumers the benefits of cost savings and convenient access through mass retail channels, while still providing high-quality care for their pets. Velcera’s flagship PetArmor® brand was supported by several pipeline product candidates in both the flea and tick and health and wellness categories that continued to bring additional products to the consumer. Velcera was acquired by Perrigo company for approximately $160 million in cash in April 2013.

Transaction Summary

  • Yardley, PA

  • Contact:
    Scott Barry
  • Acquisition
  • Acquired by: Perrigo Company
  • Exit date: April 01, 2013
  • Logo

Related News

“Essex Woodlands led our capital round, and provided so much more than the growth equity capital Velcera required. While our board had a strong chairman, the director from Essex provided effective informal leadership throughout our building stage through his knowledge, sound business judgment and professional and effective communication style. All new companies who break the status quo run into difficulties and turbulent times, and our company certainly faced our fair share of these adversities. As the CEO, I can honestly say “Thank goodness!” for the steady, calming influence of Essex on our board team. They stayed positive, looked for solutions and kept all eyes focused on the future ahead. As a result, the Essex transaction expertise proved to be invaluable as we negotiated a very successful exit.”

Dennis Steadman

Chief Executive Officer

Testimonials and endorsements reflect portfolio company management’s opinions and beliefs regarding the company and the investment. Such opinions and beliefs are subjective, do not represent a complete assessment of the company, the market or EW’s overall investment performance and cannot be independently verified. Such statements are being offered as references for purposes of demonstrating the benefits of working with the EW team and not for the purpose of soliciting investors. Portfolio company executives receive/received a salary and economics from the portfolio company. No executives were paid for their testimonial or endorsement. There is a conflict of interest in these unpaid testimonials and endorsements in that all speakers stand to benefit from EW’s success and they work/worked for an EW portfolio company.